Followers | 4046 |
Posts | 152725 |
Boards Moderated | 3 |
Alias Born | 08/05/2009 |
Monday, August 29, 2022 6:45:40 PM
Recent NERV News
- Form 8-K - Current report • Edgar (US Regulatory) • 01/13/2025 01:46:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2024 10:45:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2024 10:45:13 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2024 10:45:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 12/06/2024 10:45:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/05/2024 10:21:01 PM
- Minerva Neurosciences Reports Third Quarter 2024 Financial Results and Business Updates • GlobeNewswire Inc. • 11/05/2024 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/05/2024 12:00:18 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 10/22/2024 11:12:59 AM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 10/22/2024 11:09:49 AM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 10/22/2024 11:06:56 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/11/2024 08:10:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/16/2024 08:05:53 PM
- Minerva Neurosciences Reports Second Quarter 2024 Financial Results and Business Updates • GlobeNewswire Inc. • 08/06/2024 11:30:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/06/2024 11:01:13 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/30/2024 08:25:30 PM
- Minerva Neurosciences Reports First Quarter 2024 Financial Results and Business Updates • GlobeNewswire Inc. • 05/01/2024 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 01:04:42 PM
- Minerva Neurosciences Receives Complete Response Letter from FDA for New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia • GlobeNewswire Inc. • 02/27/2024 01:00:00 PM
- Minerva Neurosciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Business Updates • GlobeNewswire Inc. • 02/22/2024 12:00:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/22/2024 11:30:30 AM
UAV Corp Skyborne Technology Secures $105M in Sales Contract LOIs for Revolutionary DART Series Airships • UMAV • Jan 13, 2025 11:00 AM
SANUWAVE Health Announces Preliminary Revenue Results for the Fourth Quarter 2024 (Ended December 31, 2024) • SNWV • Jan 13, 2025 8:10 AM
SANUWAVE Health Appoints Industry Veteran Timothy Wern as Executive Vice President of Sales • SNWV • Jan 13, 2025 8:08 AM
North Bay Resources Announces Operation of New Gravity Circuit at Bishop Gold Mill, California • NBRI • Jan 10, 2025 8:29 AM
Cannabix Technologies Announces Key Hardware Advancements to Marijuana Breathalyzer Technology • BLO • Jan 9, 2025 8:49 AM
UAV Corp. (UMAV) Further Reduces Authorized Shares to 500 Million • UMAV • Jan 8, 2025 2:27 PM